Skip to main content

News

FDA Issues Draft Guidance on Biosimilar Interchangeability

Interchangeability, or the substitution of a biosimilar for its innovator biologic, is on the horizon. Will the prescriber chose the biosimilar in place of the originator? Or will this allow pharmacists or healthcare plans to substitute a biosimilar, without intervention from a healthcare provider?

The RheumNow Week in Review – 20 January 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.

Who Is At Risk to Lose Insurance if the ACA is Changed or Repealed?

If Congress changes or repeals the Affordable Care Act (ACA), which adults are at risk of losing health insurance?

EULAR Revised Recommendations for Fibromyalgia

The European League Against Rheumatism (EULAR) recommendations for fibromyalgia (FM) management were published in 2007 and largely had recommendations based on expert opinion’. These guidelines were updated in May of 2015 after a systematic reviews and meta-analyses of the data.

Consensus Guidelines for Juvenile Dermatomyositis Management

SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was established in 2012 to optimise the diagnosis and treatment of several pediatric diseases. They have recently published their recommendations regarding the diagnosis and management of juvenile dermatomyositis (JDM).

Dietary Intake Triggers Inflammation

IL-1β, along with pancreatic insulin, helps regulate blood sugar levels, as well as chronic inflammation.

Patient and Provider Education Fails to Improve Osteoarthritis Outcomes

A randomized trial of 537 knee osteoarthritis (OA) patients in the Duke Healthcare system has shown that patient- and provider interventions were no better than the usual standard of care.

Rituximab Effects on ANCA, IgG and Infectious Risk in ANCA-Associated Vasculitis

Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.

PPIs Reduce Post-Hip Fracture Mortality

The association between the use of proton pump inhibitors (PPIs), osteoporosis (OP) and OP-related fragility fractures has been a topic of ongoing discussion in rheumatology community.

The RheumNow Week in Review – 13 January 2017

Dr. Jack Cush reviews highlights from this past week on RheumNow.com:

Psoriatic Arthritis Patients have More Heart Disease

A study of 90 consecutive male (50.3±11.1 years) with psoriatic arthritis (PsA) were were compared to 240 age matched controls without known cardiovascular (CV) diseases who underwent angiography for chest pain and/or multiple CV risk factors.

Statins Don't Increase Risk of Colchicine Myopathy

Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.  

Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.

×